CN110916035A - Ginseng gum solid beverage and preparation method and application thereof - Google Patents
Ginseng gum solid beverage and preparation method and application thereof Download PDFInfo
- Publication number
- CN110916035A CN110916035A CN201911193282.0A CN201911193282A CN110916035A CN 110916035 A CN110916035 A CN 110916035A CN 201911193282 A CN201911193282 A CN 201911193282A CN 110916035 A CN110916035 A CN 110916035A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- parts
- solid beverage
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 56
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 54
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 54
- 235000013361 beverage Nutrition 0.000 title claims abstract description 40
- 239000007787 solid Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 241000208340 Araliaceae Species 0.000 title claims abstract 18
- 239000003814 drug Substances 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 238000000855 fermentation Methods 0.000 claims abstract description 35
- 208000006673 asthma Diseases 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 201000006306 Cor pulmonale Diseases 0.000 claims abstract description 22
- 206010014561 Emphysema Diseases 0.000 claims abstract description 22
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims abstract description 22
- 206010006451 bronchitis Diseases 0.000 claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 20
- 239000008213 purified water Substances 0.000 claims abstract description 19
- LVQDKIWDGQRHTE-UHFFFAOYSA-N cyromazine Chemical compound NC1=NC(N)=NC(NC2CC2)=N1 LVQDKIWDGQRHTE-UHFFFAOYSA-N 0.000 claims abstract description 17
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 claims abstract description 15
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims abstract description 15
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims abstract description 15
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims abstract description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 14
- 229910000365 copper sulfate Inorganic materials 0.000 claims abstract description 14
- 235000003891 ferrous sulphate Nutrition 0.000 claims abstract description 14
- 239000011790 ferrous sulphate Substances 0.000 claims abstract description 14
- 235000010855 food raising agent Nutrition 0.000 claims abstract description 14
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims abstract description 14
- 229910000368 zinc sulfate Inorganic materials 0.000 claims abstract description 14
- 229960001763 zinc sulfate Drugs 0.000 claims abstract description 14
- 239000005891 Cyromazine Substances 0.000 claims abstract description 13
- 229950000775 cyromazine Drugs 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims abstract description 11
- 241000489492 Arisaema Species 0.000 claims abstract description 9
- 210000000941 bile Anatomy 0.000 claims abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 8
- 229960000355 copper sulfate Drugs 0.000 claims abstract description 8
- 229960001781 ferrous sulfate Drugs 0.000 claims abstract description 8
- 239000008103 glucose Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 7
- 241000272814 Anser sp. Species 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 5
- 239000012265 solid product Substances 0.000 claims abstract description 5
- 239000004575 stone Substances 0.000 claims abstract description 5
- 238000010438 heat treatment Methods 0.000 claims description 27
- 230000018044 dehydration Effects 0.000 claims description 21
- 238000006297 dehydration reaction Methods 0.000 claims description 21
- 230000004151 fermentation Effects 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 12
- 239000000499 gel Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000011812 mixed powder Substances 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 244000144725 Amygdalus communis Species 0.000 claims description 6
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 6
- 241000758794 Asarum Species 0.000 claims description 6
- 241000218671 Ephedra Species 0.000 claims description 6
- 244000061508 Eriobotrya japonica Species 0.000 claims description 6
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 6
- 241000132446 Inula Species 0.000 claims description 6
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 6
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 6
- 235000020224 almond Nutrition 0.000 claims description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 6
- 235000011477 liquorice Nutrition 0.000 claims description 6
- 244000081426 Ranunculus ficaria Species 0.000 claims description 5
- 235000002226 Ranunculus ficaria Nutrition 0.000 claims description 5
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 5
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 5
- 235000015110 jellies Nutrition 0.000 claims description 5
- 239000008274 jelly Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 244000144730 Amygdalus persica Species 0.000 claims description 4
- 241000801118 Lepidium Species 0.000 claims description 4
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 4
- 240000000377 Tussilago farfara Species 0.000 claims description 4
- 235000004869 Tussilago farfara Nutrition 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 241001633574 Adenophora stricta Species 0.000 claims description 3
- 241000207929 Scutellaria Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 241000722824 Ardisia crenata Species 0.000 claims description 2
- 241000249864 Tussilago Species 0.000 claims description 2
- 241001412627 Adenophora liliifolia Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 39
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 241000628997 Flos Species 0.000 abstract description 6
- 230000000857 drug effect Effects 0.000 abstract description 6
- 230000001976 improved effect Effects 0.000 abstract description 4
- 241000572565 Alpinia oxyphylla Species 0.000 abstract description 3
- 108010052008 colla corii asini Proteins 0.000 abstract description 3
- 239000012467 final product Substances 0.000 abstract description 2
- 240000005373 Panax quinquefolius Species 0.000 description 38
- 206010011224 Cough Diseases 0.000 description 20
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010016807 Fluid retention Diseases 0.000 description 3
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000447 pesticide residue Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 241001633583 Adenophora Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- -1 fatty acid ester Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000009254 shuang-huang-lian Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000003900 soil pollution Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application discloses a ginseng gum solid beverage and a preparation method and application thereof. The ginseng gum solid beverage is a solid product obtained by adding purified water and a leavening agent into a traditional Chinese medicine composition and performing anaerobic fermentation; the Chinese medicinal composition comprises Ginseng radix, colla Corii Asini, herba Ephedrae, herba asari, Scutellariae radix, Glycyrrhrizae radix, rhizoma Pinelliae Preparata, Arisaema cum bile, Inulae flos, flos Farfarae, semen Lepidii, radix Platycodi, semen Armeniacae amarum, folium Eriobotryae, goose tube stone, radix scrophulariae, radix Adenophorae, Bulbus Fritillariae Cirrhosae, semen Persicae and fructus Alpinae Oxyphyllae; the leaven accounts for 0.005-0.02% of the total weight of the Chinese medicinal composition and the purified water, and comprises cyromazine, copper sulfate, zinc sulfate, ferrous sulfate, cobalt chloride, edible salt, sodium bicarbonate and glucose powder. The ginseng gum solid beverage adopts a novel traditional Chinese medicine composition formula and combines anaerobic fermentation treatment of a leaven, so that a final product has better drug effect, and the treatment effect of diseases such as bronchitis, asthma, pulmonary heart disease, emphysema and the like is improved.
Description
Technical Field
The invention relates to the field of Chinese patent medicines, in particular to a ginseng and propolis solid beverage as well as a preparation method and application thereof.
Background
The lower respiratory tract infection mainly comprises acute bronchitis, chronic bronchitis, bronchial asthma and other airway infections, and pulmonary parenchyma infections such as pneumonia, emphysema and pulmonary heart disease. In recent years, with the wide clinical use of antibacterial drugs, most pathogenic bacteria have different degrees of drug resistance to antibiotics, and the therapeutic effect of the antibiotics is affected. The traditional Chinese medicine or the Chinese patent medicine attaches importance to the overall recuperation of the body and the recuperation of the internal disease resistance of the body, and carries out syndrome differentiation treatment on different characteristics in the disease development process; therefore, the overall treatment concept of traditional Chinese medicine is more and more emphasized by modern medicine. For example, the first subsidiary hospital of the medical college of traditional Chinese medicine of Anhui has published a review article of "superiority of traditional Chinese medicine in treating lower respiratory tract infection", in which it is described in detail that traditional Chinese medicine treatment is not specific mainly against pathogenic bacteria, but traditional Chinese medicine emphasizes constitutional factors and emphasizes dialectical treatment, and has wide adaptability and broad development prospect.
The traditional Chinese medicine and the traditional Chinese medicine Boda are profound, and many of the traditional Chinese medicines have curative effects on lower respiratory tract infection, for example, extracts of scutellaria baicalensis and andrographis paniculata can resist various respiratory tract viruses, and Shuanghuanglian dispersible tablets also have different inhibitory effects on various viruses. However, the traditional Chinese medicine emphasizes monarch, minister, assistant and guide, and realizes the overall treatment effect by combining different traditional Chinese medicines. The existing traditional Chinese medicine preparation or Chinese patent medicine has poor treatment effect due to compatibility and composition, and cannot meet the treatment expectation easily; or the treatment effect is single, which does not accord with the concept of overall dialectical treatment of the traditional Chinese medicine and is difficult to achieve better treatment effect.
Disclosure of Invention
The application aims to provide a novel ginseng gel solid beverage for treating diseases such as bronchitis, asthma, pulmonary heart disease, emphysema and the like, and a preparation method and application thereof.
In order to achieve the purpose, the following technical scheme is adopted in the application:
the first aspect of the application discloses a ginseng jelly solid beverage, which is a solid product obtained by adding purified water and a leaven into a traditional Chinese medicine composition and performing anaerobic fermentation; wherein the Chinese medicinal composition comprises Ginseng radix, colla Corii Asini, herba Ephedrae, herba asari, Scutellariae radix, Glycyrrhrizae radix, rhizoma Pinelliae Preparata, Arisaema cum bile, Inulae flos, flos Farfarae, semen Lepidii, radix Platycodi, semen Armeniacae amarum, folium Eriobotryae, goose tube stone, radix scrophulariae, radix Adenophorae, Bulbus Fritillariae Cirrhosae, semen Persicae and fructus Alpinae Oxyphyllae; the leaven accounts for 0.005-0.02% of the total weight of the traditional Chinese medicine composition and the purified water, and consists of 0.02-0.03 part of cyromazine, 0.2-0.4 part of copper sulfate, 0.6-0.8 part of zinc sulfate, 0.3-0.6 part of ferrous sulfate, 0.6-0.7 part of cobalt chloride, 0.1-0.2 part of edible salt, 0.3-0.4 part of baking soda and 0.5-1.5 parts of glucose powder.
It should be noted that the ginseng jelly solid beverage of the present application, also known as Qianjin powder, wherein a proper amount of ginseng has an excitatory effect on the central nervous system, but a large amount of ginseng has an inhibitory effect; colla Corii Asini can be used for treating blood deficiency, sallow complexion, vertigo, and palpitation; herba Ephedrae can be used for inducing sweat, relieving exterior syndrome, dispersing lung qi, relieving asthma, inducing diuresis, relieving swelling, and relieving asthma and cough; herba asari has effects in relieving exterior syndrome, dispelling cold, expelling pathogenic wind, relieving pain, inducing resuscitation, warming lung, and promoting fluid retention, and can be used for treating common cold due to wind-cold, headache, toothache, nasal obstruction, watery nasal discharge, allergic rhinitis, nasosinusitis, rheumatalgia, phlegm, fluid retention, asthma, and cough; baikal skullcap root has effects of purging excess fire, eliminating dampness and heat, stopping bleeding, and preventing miscarriage, and is commonly used for treating high fever, polydipsia, lung heat cough, damp-heat dysentery, jaundice, heat stranguria, emesis, epistaxis, metrorrhagia, conjunctival congestion, swelling and pain, threatened abortion, carbuncle, furuncle, etc.; for internal organs, cold and heat, strengthening muscles and bones, strengthening muscles, strengthening strength, removing toxic substances, reducing weight, prolonging life, purging pathogenic fire and heat when used unprocessed, dispelling exterior cold when used cooked, relieving pharyngalgia, removing pathogenic heat, relieving vital qi, nourishing yin and blood, invigorating spleen and stomach, and moistening lung; rhizoma Pinelliae Preparata eliminates dampness and phlegm, and is used for treating cough with excessive phlegm, dizziness and palpitation due to phlegm-fluid retention, dizziness and headache due to wind-phlegm; arisaema cum bile clears fire and reduces phlegm, relieves convulsion and arresting epilepsy, and is used for treating apoplexy with phlegm, convulsion and epilepsy, phlegm-fire asthma and cough, and dizziness; inulae flos has effects of eliminating phlegm, descending qi, softening hard masses, and promoting diuresis, and can be used for treating phlegm stagnation in chest, distention and fullness in hypochondrium, cough and asthma, singultus, saliva such as resina Toxicodendri, epigastric fullness , hiccup, and edema of large abdomen; flos Farfarae is used for treating chronic cough, asthma, over-strained cough, hemoptysis, moistening lung, and relieving cough; semen Lepidii has effects of relieving cough and promoting diuresis; radix Platycodi has antitussive, expectorant, lung ventilating, and pus discharging effects; semen Armeniacae amarum has effects of relieving cough and asthma, loosening bowel to relieve constipation, and can be used for treating pulmonary disease, cough, etc.; loquat leaf has the effects of clearing lung-heat, relieving cough, harmonizing stomach, promoting urination and quenching thirst, and is commonly used for treating lung heat phlegm cough, hemoptysis, epistaxis, stomach heat vomiturition and the like; the product can be used for treating pulmonary tuberculosis cough, chest distress, sexual impotence, asthenia of waist and knees, and galactostasis; radix scrophulariae is commonly used for warm diseases, nutrient and blood, fever, polydipsia, crimson tongue, macula, bone-steaming, overstrain cough, dysphoria, body fluid impairment constipation, dryness and dim eyesight, sore throat and throat, scrofula and subcutaneous nodule, superficial infection and sore toxicity; radix Adenophorae is used for treating tracheitis, pertussis, cough due to lung heat, yellow and thick expectoration, etc.; bulbus Fritillariae Cirrhosae has effects of resolving stagnation in chest and diaphragm, eliminating phlegm, lowering qi, relieving cough, and resolving stagnation; semen Persicae has effects of promoting blood circulation, removing blood stasis, loosening bowel to relieve constipation, relieving cough and asthma, and is often used for treating amenorrhea, dysmenorrhea, abdominal mass, lump in the abdomen, lung abscess, intestinal abscess, traumatic injury, intestinal dryness, constipation, cough, asthma, etc.; fructus Alpinae Oxyphyllae has the effects of warming spleen, relieving diarrhea, warming kidney, arresting polyuria, and stopping nocturnal emission, and is often used for treating spleen and stomach deficiency cold, emesis, diarrhea, abdominal psychroalgia, excessive saliva, kidney deficiency, enuresis, pollakisuria, nocturnal emission, whitish and turbid urine, etc.
The formula of the traditional Chinese medicine composition is optimized, and the fermentation effect of the leavening agent is combined, so that the finally formed ginseng gel solid beverage can better exert the drug effect, and has better effect of treating diseases such as bronchitis, asthma, pulmonary heart disease, emphysema and the like. The leaven is a compound preparation which is specially developed by the application and can promote the growth and fermentation of environmental microorganisms carried by the traditional Chinese medicine composition; the anaerobic fermentation by adopting the composite preparation has the following effects: (1) heavy metal and pesticide residue contained in the medicinal materials can be decomposed and converted, and the problems that the heavy metal of the Chinese medicinal materials exceeds the standard and the pesticide residue of the Chinese medicinal materials is remained due to soil pollution or pesticide residue exceeding the standard in the planting process are solved; (2) effective active ingredients of the Chinese medicinal materials of all components can be fully released through fermentation and organically combined together, so that the common effect of mutual compatibility of all the components is really achieved, and the treatment effect is improved; (3) through the fermentation of the leaven, the content of probiotics carried by the traditional Chinese medicine composition can be increased, the content of prebiotics is increased, the toxic and side effects in the taking process can be reduced under the action of the probiotics and the prebiotics, and the harm to the human body is avoided.
Preferably, the traditional Chinese medicine composition comprises 50 parts by weight of ginseng, 30 parts by weight of donkey-hide gelatin, 30 parts by weight of ephedra herb, 30 parts by weight of asarum herb, 20 parts by weight of scutellaria baicalensis, 30 parts by weight of liquorice, 20 parts by weight of rhizoma pinellinae praeparata, 20 parts by weight of arisaema cum bile, 30 parts by weight of inula flower, 30 parts by weight of tussilago farfara, 30 parts by weight of semen lepidii, 30 parts by weight of platycodon grandiflorum, 30 parts by weight of almond, 50 parts by.
Preferably, the amount of purified water added to the Chinese medicinal composition is 35L per 50g of ginseng.
It should be noted that the weight parts of the components and the amount of purified water added correspondingly in the traditional Chinese medicine composition are only the dosage of the formula specifically adopted in one implementation manner of the present application; it is understood that the above amount can be adjusted as appropriate according to the specific situation, for example, the amount of each component is increased or decreased by about 5%. The pure water is used for fully mixing and fermenting all the components; the pure water consumption is too low, and the components are not mixed, so that the mixing is not uniform, the performance of the compatibility drug property is influenced, or the drug property is unstable and non-uniform; if the consumption of the purified water is too high, the common properties of all the components are difficult to organically combine together through fermentation, and the drug effect is also influenced.
Preferably, the anaerobic fermentation is performed at low temperature for 10-20 days.
The aim of low-temperature fermentation is to avoid the influence of high temperature on the drug effect; on the other hand, low temperature fermentation is beneficial to the growth of probiotics. As regards the number of days of fermentation, it is mainly the organic combination of the components and the contents of probiotics and prebiotics that are affected; it will be appreciated that too short a fermentation time will not achieve the desired effect, and that too long a fermentation time will be time consuming, and that part of the drug or prebiotic will be consumed by the probiotic, which will itself enter the stationary or decline phase of growth.
Preferably, the low temperature is 40-50 ℃.
The application also discloses application of the ginseng gel solid beverage in preparation of medicines for treating bronchitis, asthma, pulmonary heart disease or emphysema.
In another aspect of the present application, a pharmaceutical composition for treating bronchitis, asthma, pulmonary heart disease or emphysema, which contains the ginseng gum solid beverage of the present application as an effective active ingredient, is disclosed.
The ginseng glue solid beverage has the advantages that the formula of the traditional Chinese medicine composition has the effect of treating bronchitis, asthma, pulmonary heart disease and emphysema, and the efficacy of the ginseng glue solid beverage can be more effectively exerted by combining with the fermentation agent for fermentation, so that the ginseng glue solid beverage can be used for treating bronchitis, asthma, pulmonary heart disease or emphysema, or can be prepared into corresponding treatment medicines.
Preferably, the pharmaceutical composition of the present application further comprises pharmaceutically acceptable adjuvants or auxiliary components.
The pharmaceutically acceptable auxiliary materials or auxiliary components of the ginseng gum solid beverage mainly refer to glucose, lactose, sucrose, starch, mannitol, dextrin, fatty glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, gelatin, albumin, water, physiological saline and the like, and the ginseng gum solid beverage is prepared into medicines of various dosage forms; alternatively, the ginseng gum solid beverage in powder form may be used without using these auxiliary materials or auxiliary components. The dosage form of the pharmaceutical composition may be any dosage form, and is not particularly limited.
The application further discloses a preparation method of the ginseng gel solid beverage, which comprises the following steps:
(1) weighing ginseng, donkey-hide gelatin, ephedra, asarum, scutellaria, liquorice, rhizoma pinellinae praeparata, arisaema cum bile, inula flower, tussilago flower, pepperweed seed, platycodon grandiflorum, almond, loquat leaf, goose tube stone, figwort, adenophora stricta, bulbus fritillariae cirrhosae, peach kernel and fructus alpiniae oxyphyllae in parts by weight, and processing the components into powder; wherein, each component is dry medicinal materials;
(2) uniformly dispersing the powder material in the step (1) into purified water at 65-75 ℃, adding a leavening agent, uniformly stirring, and carrying out anaerobic fermentation at a constant temperature of 40-50 ℃ for 10-20 days in a sealed environment;
(3) and (3) drying and crushing the fermentation product obtained in the step (2) to obtain the ginseng gel solid beverage.
In the preparation method, the components are processed into powder in the step (1) for the purpose of facilitating fermentation and better exerting the drug effect; in one implementation of the present application, the particle size of the powder is 145-155 mesh, preferably 150 mesh.
Preferably, the drying temperature in the step (3) is 50-55 ℃.
It should be noted that the drying is mainly for removing moisture, but not for affecting the efficacy of the drug at too high a temperature, and therefore, it is preferably 50-55 ℃.
Preferably, in the preparation method of the application, the leaven is prepared by adopting the following method,
(1) carrying out heat treatment dehydration on cyromazine, copper sulfate, zinc sulfate, ferrous sulfate and cobalt chloride respectively;
(2) mixing the heat-treated and dehydrated cyromazine, copper sulfate, zinc sulfate, ferrous sulfate and cobalt chloride with salt, glucose powder and sodium bicarbonate according to weight percentage, and grinding to prepare mixed powder;
(3) and (3) drying the mixed powder in the step (2) under the conditions of no oxygen and light shielding to obtain the leavening agent.
Preferably, in step (1), the dehydration by heat treatment is carried out under oxygen-free conditions.
Preferably, in the step (1), the heat treatment dehydration condition of cyromazine is 140-150 ℃ for 100-120 minutes, the heat treatment dehydration condition of copper sulfate is 85-95 ℃ for 75-85 minutes, the heat treatment dehydration condition of zinc sulfate is 95-100 ℃ for 100-120 minutes, the heat treatment dehydration condition of ferrous sulfate is 100-120 ℃ for 60-70 minutes, and the heat treatment dehydration condition of cobalt chloride is 135-145 ℃ for 140-150 minutes.
Preferably, in the step (2), the particle size of the mixed powder is 300 meshes.
Preferably, in the step (3), the drying condition is 55-65 ℃ for 30-35 hours.
The beneficial effect of this application lies in:
the ginseng gum solid beverage adopts a novel traditional Chinese medicine composition formula and combines anaerobic fermentation treatment of a leaven, so that a final product has better drug effect, and the treatment effect of diseases such as bronchitis, asthma, pulmonary heart disease, emphysema and the like is improved.
Detailed Description
In view of the problems of poor treatment effect and the like of the traditional Chinese medicine preparation for treating diseases such as bronchitis, asthma, pulmonary heart disease, emphysema and the like at present, the inventor of the application develops a novel traditional Chinese medicine composition capable of treating bronchitis, asthma, pulmonary heart disease and emphysema simultaneously according to years of traditional Chinese medicine practice experience and practice; in combination with the principle of environmental microbial preparation, a new leaven is developed to carry out anaerobic fermentation on the formula of the traditional Chinese medicine composition; thereby obtaining the ginseng gel solid beverage of the present application. The ginseng gel solid beverage is a solid product obtained by adding purified water and a fermenting agent into a traditional Chinese medicine composition and performing anaerobic fermentation, namely removing water in the traditional Chinese medicine composition after the anaerobic fermentation.
Wherein, the purified water refers to water without impurities or bacteria, and is called purified water or purified water for short; the purpose of using purified water is to avoid the introduction of other interfering components by the water. The important innovation of the application is that firstly, a new traditional Chinese medicine composition formula is adopted; second, a special starter for activating the growth of microorganisms is used. The leaven is obtained by long-term and deep research and optimization of the inventor, mainly comprises some conventional chemical agents, has small dosage, can quickly activate a large amount of probiotics such as lactic acid bacteria in the traditional Chinese medicine composition, does not need to additionally add beneficial bacteria, and has low cost.
In order to improve the effect of the leavening agent for activating the growth of microorganisms, the leavening agent is prepared by a special preparation method. Specifically, the method comprises the following steps:
(1) carrying out heat treatment dehydration on cyromazine, copper sulfate, zinc sulfate, ferrous sulfate and cobalt chloride respectively;
(2) mixing the heat-treated and dehydrated cyromazine, copper sulfate, zinc sulfate, ferrous sulfate and cobalt chloride with salt, glucose powder and sodium bicarbonate according to weight percentage, and grinding to prepare mixed powder;
(3) drying the mixed powder in the step (2) under the conditions of no oxygen and light shielding to obtain the leavening agent;
wherein, in the step (1), the heat treatment dehydration is carried out under the anaerobic condition; the heat treatment dehydration condition of the cyromazine is 140-150 ℃ for 100-120 minutes, the heat treatment dehydration condition of the copper sulfate is 85-95 ℃ for 75-85 minutes, the heat treatment dehydration condition of the zinc sulfate is 95-100 ℃ for 100-120 minutes, the heat treatment dehydration condition of the ferrous sulfate is 100-120 ℃ for 60-70 minutes, and the heat treatment dehydration condition of the cobalt chloride is 135-145 ℃ for 140-150 minutes; in the step (2), the particle size of the mixed powder is 300 meshes; in the step (3), the drying condition is that the treatment is carried out for 30 to 35 hours at the temperature of between 55 and 65 ℃.
In the starter, cyromazine is a disinfectant and harmless to people, and the starter retains weak disinfection function after being treated by the preparation method and can inhibit aspergillus flavus and other harmful bacteria in the traditional Chinese medicine composition; and the beneficial flora quantity such as lactobacillus is dominant, so that the cyromazine does not influence the growth of the beneficial flora such as lactobacillus, but rapidly grows under the activation of the leavening agent. Other components are dehydrated through special heat treatment, so that the toxicity is reduced, and the components are combined with each other to play a role in promoting the growth of probiotics in the traditional Chinese medicine composition.
The present application will be described in further detail with reference to specific examples. The following examples are intended to be illustrative of the present application only and should not be construed as limiting the present application.
Examples
Firstly, preparation of leaven
10g of cyromazine, copper sulfate, zinc sulfate, ferrous sulfate and cobalt chloride are weighed respectively. Cyromazine was dehydrated by heat treatment in an oven at a temperature of 145 ℃ for 110 minutes, copper sulfate was dehydrated by heat treatment in an oven at a temperature of 90 ℃ for 80 minutes, zinc sulfate was dehydrated by heat treatment in an oven at a temperature of 95 ℃ for 110 minutes, ferrous sulfate was dehydrated by heat treatment in an oven at a temperature of 110 ℃ for 65 minutes, and cobalt chloride was dehydrated by heat treatment in an oven at a temperature of 140 ℃ for 145 minutes.
Weighing 0.3g of heat-treated and dehydrated cyromazine, 4g of heat-treated and dehydrated copper sulfate, 8g of heat-treated and dehydrated zinc sulfate, 5g of heat-treated and dehydrated ferrous sulfate, 7g of heat-treated and dehydrated cobalt chloride, and weighing 2g of edible salt, 4g of baking soda and 12g of glucose powder, uniformly mixing the components, fully grinding by using a mortar, and sieving by using a 300-mesh sieve. Then, the sieved powder mixture was dried in an oven at 65 ℃ under oxygen-exclusion and light-shielding conditions for 32 hours to obtain the fermentation broth of this example.
Preparation of ginseng and American ginseng solid beverage
Weighing 50g of ginseng, 30g of donkey-hide gelatin, 30g of ephedra, 30g of asarum, 20g of scutellaria baicalensis, 30g of liquorice, 20g of rhizoma pinellinae praeparata, 20g of arisaema cum bile, 30g of inula flower, 30g of tussilago farfara, 30g of lepidium seed, 30g of platycodon grandiflorum, 30g of almond, 50g of loquat leaf, 40g of coral ardisia, 30g of figwort root, 30g of adenophora, 40g of bulbus fritillariae cirrhosae, 40g of peach kernel and 30g of fructus alpiniae oxyphyllae, and processing the components into 150; mixing the powder materials, placing the powder materials in a container, adding 35L of purified water with the temperature of 70 ℃, uniformly stirring the mixture, adding 6g of prepared leavening agent, uniformly stirring the mixture, placing the mixture in a sealed container, carrying out anaerobic constant-temperature fermentation for 15 days at the temperature of 45 ℃, after the fermentation is finished, drying the mixture at the low temperature of 55 ℃, and crushing the mixture to obtain the ginseng gel solid beverage. The markers were labeled as test groups.
Preparation of comparative test material without addition of leaven
The process was carried out according to the recipe and fermentation step of "preparation of ginseng and ginseng solid beverage", except that no starter was added and the final prepared solid product was labeled as comparative test 1.
Preparation of comparative test material of pure traditional Chinese medicine composition
According to the formula of 'preparation of ginseng and American ginseng solid beverage', the components are directly weighed, processed into 150-mesh powder and uniformly mixed to serve as a comparative test 2.
Fifth, test of drug action
In this example, 90 bronchitis patients, 90 asthma patients, 90 pulmonary heart disease patients and 90 emphysema patients were treated, and all patients were signed with informed consent according to relevant regulations.
Patients with different diseases were divided equally into three groups, 30 per group:
the first group, 30 patients with bronchitis, 30 patients with asthma, 30 patients with pulmonary heart disease, and 30 patients with emphysema; taking Ginseng radix and Ginseng radix gel solid beverage for 10g three times a day for 7 days, and marking as test group.
The second group, 30 patients with bronchitis, 30 patients with asthma, 30 patients with pulmonary heart disease, and 30 patients with emphysema; taking the traditional Chinese medicine prepared from the comparative test material without the leaven three times a day, 10g each time, continuously taking for 7 days, and marking as comparative test 1.
The third group, 30 patients with bronchitis, 30 patients with asthma, 30 patients with pulmonary heart disease, and 30 patients with emphysema; the four-drug pure traditional Chinese medicine composition is taken three times a day, 10g of the traditional Chinese medicine composition is taken each time, and the traditional Chinese medicine composition is continuously taken for 7 days and is marked as a comparative experiment 2.
The judgment standard of the treatment effect is as follows:
and (3) healing: the symptom is reduced by more than 95 percent, and the relevant sign experiment indexes are recovered to be normal.
The effect is shown: the symptom is reduced by more than 75 percent, and the related signs and the experimental indexes are basically normal.
The method has the following advantages: the symptoms are reduced by more than 30 percent, and related signs and experimental indexes are improved.
And (4) invalidation: the symptom is reduced by less than 30 percent, and related signs and experimental indexes are unchanged.
The statistical results of the three groups of tests are as follows:
a first group:
30 patients with bronchitis: 26 cases are cured, 3 cases are obviously effective, and 1 case is effective;
30 asthmatic patients: 25 cases are cured, 3 cases are obviously effective, and 2 cases are effective;
30 patients with pulmonary heart disease: the medicine is used for treating 20 cases, 5 cases with obvious effect, 4 cases with effect and 1 case with no effect;
30 patients with emphysema: 19 cases are cured, 4 cases are obviously effective, 5 cases are effective, and 2 cases are ineffective;
second group:
30 patients with bronchitis: the medicine is used for treating 20 cases, 5 cases with obvious effect, 4 cases with effect and 1 case with no effect;
30 asthmatic patients: 21 cases are cured, 4 cases are obviously effective, 2 cases are effective, and 3 cases are ineffective;
30 patients with pulmonary heart disease: 17 cases are cured, 9 cases are obviously effective, 2 cases are effective, and 2 cases are ineffective;
30 patients with emphysema: 15 cases are cured, 8 cases are obviously effective, 6 cases are effective, and 1 case is ineffective;
third group:
30 patients with bronchitis: 15 cases are cured, 10 cases are obviously effective, 3 cases are effective, and 2 cases are ineffective;
30 asthmatic patients: 16 cases are cured, 9 cases are obviously effective, 4 cases are effective, and 1 case is ineffective;
30 patients with pulmonary heart disease: 12 cases are cured, 13 cases are obviously effective, 3 cases are effective, and 2 cases are ineffective;
30 patients with emphysema: 11 cases are cured, 12 cases are obviously effective, 6 cases are effective, and 1 case is ineffective.
The above results show that the ginseng jelly solid beverage of the present example has a better therapeutic effect, while the traditional Chinese medicine composition without fermentation has a poor effect, and particularly for pulmonary heart disease and emphysema, the ginseng jelly solid beverage of the present example can have a better curative effect. In general, the traditional Chinese medicine composition has a treatment effect on bronchitis, asthma, pulmonary heart disease and emphysema, and the ginseng gel solid beverage prepared by the traditional Chinese medicine composition after anaerobic fermentation by the leavening agent has a better treatment effect.
The foregoing is a more detailed description of the present application in connection with specific embodiments thereof, and it is not intended that the present application be limited to the specific embodiments thereof. It will be apparent to those skilled in the art from this disclosure that many more simple derivations or substitutions can be made without departing from the spirit of the disclosure.
Claims (10)
1. A ginseng jelly solid beverage is characterized in that: the ginseng gum solid beverage is a solid product obtained by adding purified water and a leavening agent into a traditional Chinese medicine composition and performing anaerobic fermentation;
the traditional Chinese medicine composition is composed of ginseng, donkey-hide gelatin, ephedra, asarum, scutellaria, liquorice, rhizoma pinellinae praeparata, arisaema cum bile, inula flower, tussilago farfara, pepperweed seed, platycodon grandiflorum, almond, loquat leaf, goose tube stone, figwort, adenophora stricta, bulbus fritillariae cirrhosae, peach kernel and fructus alpiniae oxyphyllae;
the leaven accounts for 0.005-0.02% of the total weight of the traditional Chinese medicine composition and the purified water, and consists of 0.02-0.03 part of cyromazine, 0.2-0.4 part of copper sulfate, 0.6-0.8 part of zinc sulfate, 0.3-0.6 part of ferrous sulfate, 0.6-0.7 part of cobalt chloride, 0.1-0.2 part of edible salt, 0.3-0.4 part of baking soda and 0.5-1.5 parts of glucose powder.
2. The ginseng solid beverage according to claim 1, wherein: the traditional Chinese medicine composition comprises, by weight, 50 parts of ginseng, 30 parts of donkey-hide gelatin, 30 parts of ephedra, 30 parts of asarum, 20 parts of scutellaria baicalensis, 30 parts of liquorice, 20 parts of rhizoma pinellinae praeparata, 20 parts of arisaema cum bile, 30 parts of inula flower, 30 parts of common coltsfoot flower, 30 parts of semen lepidii, 30 parts of platycodon grandiflorum, 30 parts of almond, 50 parts of loquat leaf, 40 parts of coral ardisia, 30 parts of figwort root, 30 parts of straight ladybell root.
3. The ginseng solid beverage according to claim 2, wherein: the amount of purified water added to the traditional Chinese medicine composition is that 35L of purified water is added to every 50g of ginseng.
4. The ginseng solid beverage according to any one of claims 1 to 3, wherein: the anaerobic fermentation condition is low-temperature fermentation for 10-20 days;
preferably, the low temperature is 40-50 ℃.
5. Use of the ginseng gel solid beverage according to any one of claims 1 to 4 for the preparation of a medicament for the treatment of bronchitis, asthma, pulmonary heart disease or emphysema.
6. A pharmaceutical composition for treating bronchitis, asthma, pulmonary heart disease or emphysema, characterized by: the effective active ingredient of the pharmaceutical composition is the ginseng solid beverage as described in any one of claims 1 to 4.
7. The pharmaceutical composition of claim 6, wherein: the pharmaceutical composition also comprises pharmaceutically acceptable auxiliary materials or auxiliary components.
8. The method for preparing a ginseng solid beverage according to any one of claims 1 to 4, wherein: comprises the following steps of (a) carrying out,
(1) weighing ginseng, donkey-hide gelatin, ephedra, asarum, scutellaria, liquorice, rhizoma pinellinae praeparata, arisaema cum bile, inula flower, tussilago flower, pepperweed seed, platycodon grandiflorum, almond, loquat leaf, goose tube stone, figwort, adenophora stricta, bulbus fritillariae cirrhosae, peach kernel and fructus alpiniae oxyphyllae in parts by weight, and processing the components into powder;
(2) uniformly dispersing the powder material obtained in the step (1) into purified water at 65-75 ℃, adding the leavening agent, uniformly stirring, and carrying out anaerobic fermentation at a constant temperature of 40-50 ℃ for 10-20 days in a sealed environment;
(3) and (3) drying and crushing the fermentation product obtained in the step (2) to obtain the ginseng gel solid beverage.
9. The method of claim 8, wherein: the particle size of the powder in the step (1) is 145-155 meshes;
preferably, the drying temperature in the step (3) is 50-55 ℃.
10. The production method according to claim 8 or 9, characterized in that: the leavening agent is prepared by adopting the following method,
(1) carrying out heat treatment dehydration on cyromazine, copper sulfate, zinc sulfate, ferrous sulfate and cobalt chloride respectively;
(2) mixing the heat-treated and dehydrated cyromazine, copper sulfate, zinc sulfate, ferrous sulfate and cobalt chloride with salt, glucose powder and sodium bicarbonate according to weight percentage, and grinding to prepare mixed powder;
(3) drying the mixed powder in the step (2) under the conditions of no oxygen and light shielding to obtain the leavening agent;
preferably, in the step (1), the heat treatment dehydration is carried out under the anaerobic condition;
preferably, in the step (1), the heat treatment dehydration condition of cyromazine is 140-150 ℃ for 100-120 minutes, the heat treatment dehydration condition of copper sulfate is 85-95 ℃ for 75-85 minutes, the heat treatment dehydration condition of zinc sulfate is 95-100 ℃ for 100-120 minutes, the heat treatment dehydration condition of ferrous sulfate is 100-120 ℃ for 60-70 minutes, and the heat treatment dehydration condition of cobalt chloride is 135-145 ℃ for 140-150 minutes;
preferably, in the step (2), the particle size of the mixed powder is 300 meshes;
preferably, in the step (3), the drying condition is 55-65 ℃ for 30-35 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911193282.0A CN110916035A (en) | 2019-11-28 | 2019-11-28 | Ginseng gum solid beverage and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911193282.0A CN110916035A (en) | 2019-11-28 | 2019-11-28 | Ginseng gum solid beverage and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110916035A true CN110916035A (en) | 2020-03-27 |
Family
ID=69846836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911193282.0A Withdrawn CN110916035A (en) | 2019-11-28 | 2019-11-28 | Ginseng gum solid beverage and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110916035A (en) |
-
2019
- 2019-11-28 CN CN201911193282.0A patent/CN110916035A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101045133A (en) | External use medicine for treating burns or scald or skin lesion, and its preparing method | |
| CN101143171B (en) | Traditional Chinese medicine and its preparation method and its application | |
| CN102240353A (en) | Traditional Chinese drug anesthetic and preparation method thereof | |
| CN104383318A (en) | Chinese traditional medicine composition for treating tuberculosis and preparation method of Chinese traditional medicine composition | |
| CN101125187B (en) | Traditional Chinese medicinal plaster for treating pulmonary tuberculosis | |
| CN110916035A (en) | Ginseng gum solid beverage and preparation method and application thereof | |
| CN104189725A (en) | Traditional Chinese medicine composition for treating infantile asthma | |
| CN112168947A (en) | Traditional Chinese medicine composition for treating pneumonia and preparation method thereof | |
| CN104324201A (en) | Traditional Chinese medicine preparation for treating urinary system infection and production method | |
| CN100352449C (en) | Medicament composition for treating tinea pedis and tinea corporis | |
| CN103520550A (en) | Traditional Chinese medicine for treating external cold internal rheum type chronic bronchitis and preparation method thereof | |
| CN107789525A (en) | It is a kind of to treat the medicine of ulcer on the shank ulcer for many years not more and preparation method thereof | |
| CN103751743B (en) | A kind of traditional Chinese medicine pill treating chronic obstructive pulmonary disease and preparation method thereof | |
| CN101249204B (en) | Pulmonary tuberculosis treating Chinese medicine | |
| CN106389589A (en) | Medicine with effect of relieving cough and reducing sputum | |
| CN106109904A (en) | One treats phthisical Chinese medicine and preparation method thereof | |
| CN111329918A (en) | Traditional Chinese medicine composition for treating oral ulcer and preparation method thereof | |
| CN104815293A (en) | Traditional Chinese medicine tablet for treating otitis media and preparation method thereof | |
| CN105362516A (en) | Tincture for treating plasmacellular mastitis and preparation method thereof | |
| CN105031444A (en) | Traditional Chinese medicinal composition for treating primary tuberculosis | |
| CN105055886A (en) | Traditional Chinese medicine composite for treating both-qi-and-yin-deficiency type tuberculosis | |
| CN104840823A (en) | Traditional Chinese medicine preparation for treating otitis media and preparation method | |
| CN104083733A (en) | Traditional Chinese medicine preparation for cold-type children's bronchitis | |
| CN100364576C (en) | Vagina applied Chinese medicinal preparation for treating profuse leukorrhea and cervical erosion and preparation method thereof | |
| CN105497320A (en) | Gypsum-natural indigo powder for treating aphtha |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200327 |